|
Jan 09, 2023
|
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases
|
|
|
Jan 05, 2023
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Jan 04, 2023
|
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
|
|
